All Trials

Phase I/II, Multi-Center, Open-Label Study of VT3989, Alone or in Combination, in Patients With Locally Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced mesothelioma or solid tumors harboring Hippo pathway dysregulation (e.g., NF2 loss or YAP/TAZ alterations), ECOG 0–1, receive the oral TEAD inhibitor VT3989 (blocks TEAD autopalmitoylation to inhibit YAP/TAZ–TEAD signaling) as monotherapy or in combination. Combination cohorts include treatment-naïve unresectable/metastatic mesothelioma with nivolumab/ipilimumab and EGFR-mutant NSCLC (ex19del/L858R) with osimertinib; key exclusions include active CNS disease and prior TEAD inhibitors.

ClinicalTrials.gov ID: NCT04665206

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adults with advanced solid tumors or lymphomas, including molecularly defined cohorts such as ARID1A-mutant endometrial/ovarian clear cell and other solid tumors, BAP1-loss mesothelioma, PTCL/DLBCL (including EZH2-mutant), and mCRPC. Investigational therapy is tulmimetostat (CPI-0209), an oral dual EZH2/EZH1 inhibitor, given as monotherapy across cohorts and combined with enzalutamide in mCRPC.

ClinicalTrials.gov ID: NCT04104776

Phase 2 Study of Sacituzumab Govitecan-hziy in Patients With Previously Treated Mesothelioma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously treated diffuse pleural mesothelioma (post platinum/pemetrexed and/or immunotherapy) receive sacituzumab govitecan-hziy, a Trop-2–targeted antibody–drug conjugate delivering SN-38, with imaging-based response assessment by modified RECIST. Key eligibility includes measurable disease, ECOG 0 or KPS ≥70%, adequate organ function, and willingness for biopsies; notable exclusions include significant uncontrolled comorbidities and active uncontrolled viral infections.

ClinicalTrials.gov ID: NCT06477419

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adults with symptomatic KSHV-associated MCD or KICS (many HIV-positive) with at least one symptom and lab abnormality, ECOG ≤3, and without life/organ-threatening disease or symptomatic visceral KS. Single-arm therapy is pacritinib 200 mg PO BID for up to 24 weeks; pacritinib is a JAK2/TYK2-family and IRAK1 inhibitor that suppresses IL-1/IL-6 signaling (including gp130/vIL-6), aiming to improve inflammatory symptoms and labs and assess effects on concurrent Kaposi sarcoma.

ClinicalTrials.gov ID: NCT06052618

A Phase 2 Trial of Ixazomib for Kaposi Sarcoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study of oral ixazomib, a reversible 20S proteasome inhibitor, for adults with measurable cutaneous Kaposi sarcoma (HIV-positive on stable ART or HIV-negative), excluding symptomatic visceral disease and significant neuropathy/comorbidities. Ixazomib is given on days 1, 8, and 15 of 28-day cycles for up to 12–24 cycles, with efficacy by ACTG response and close safety/virologic monitoring.

ClinicalTrials.gov ID: NCT04305691

Phase I/II Study of PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with biopsy‑proven advanced Kaposi sarcoma (HIV+ on stable ART or HIV−), ECOG 0–2, and ≥5 measurable cutaneous lesions; prior systemic therapy allowed. Investigational IL‑12–targeted immunocytokine PDS01ADC (NHS‑IL12) is given subcutaneously every 28 days as monotherapy or combined with bintrafusp alfa (M7824), a bifunctional PD‑L1 blocker/TGF‑β trap given IV q2w.

ClinicalTrials.gov ID: NCT04303117

Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic or unresectable sarcomas (conventional and dedifferentiated chondrosarcoma, osteosarcoma, chordoma, and most soft tissue sarcomas except WD/DD liposarcoma) with intact Rb and evidence of CDK pathway activation receive abemaciclib 200 mg PO BID. Abemaciclib is a selective CDK4/6 inhibitor targeting Cyclin D–CDK4/6–Rb signaling; prior CDK4/6 inhibitor exposure is excluded.

ClinicalTrials.gov ID: NCT04040205

A Phase II Study of Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with relapsed/refractory primary effusion lymphoma (including extracavitary/KSHV-associated large cell lymphoma), plasmablastic lymphoma, or symptomatic KSHV-associated multicentric Castleman disease (HIV+ or HIV–, ECOG up to 3) receive subcutaneous daratumumab monotherapy. Daratumumab is an anti-CD38 monoclonal antibody that induces cytotoxicity and depletes CD38+ immunosuppressive cells; dosing is weekly then spaced to every 2–4 weeks depending on cohort.

ClinicalTrials.gov ID: NCT05907759

MISTOSUS: Iscador® P (Mistletoe) Immunotherapy To Improve Event Free Survival In Patients With Relapsed Osteosarcoma After Resection Of Pulmonary Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study for patients aged 8 to <30 with relapsed osteosarcoma who have had complete resection of all pulmonary metastases within 8 weeks, good organ function, and no active extra-pulmonary disease. Participants receive subcutaneous Iscador P (Viscum album mistletoe extract) three times weekly with individualized dose escalation for up to 52 weeks; the extract is an immunomodulatory biologic with lectins/viscotoxins aiming to enhance anti-tumor immunity and potential cytotoxicity.

ClinicalTrials.gov ID: NCT05726383

Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm trial of pembrolizumab (anti–PD-1) 200 mg IV q3w in adults with histologically confirmed cutaneous or dermal soft tissue sarcomas excluding angiosarcoma that are metastatic, unresectable, recurrent, or multifocal, with measurable disease and ECOG 0–1. Prior therapies allowed (no prior PD-1/PD-L1), controlled HIV/HBV/HCV and treated/stable brain metastases permitted.

ClinicalTrials.gov ID: NCT07007273